What Is a Bispecific Antibody? Explained for Lung Cancer Research

A bispecific antibody is an engineered antibody designed to bind two different targets at once — for example, both PD-L1 and VEGF-A — combining two mechanisms of action in a single molecule.

Traditional antibody-based cancer drugs are typically designed to bind a single target. Bispecific antibodies are engineered to recognize two different targets simultaneously, which researchers hope can address resistance mechanisms that limit single-target drugs, or allow two complementary mechanisms — such as immune checkpoint blockade and anti-blood-vessel-growth activity — to work together.

In lung cancer research specifically, several bispecific antibodies currently in trials are designed to block both an immune checkpoint protein (like PD-L1) and VEGF, a driver of tumor blood vessel growth, based on the idea that these two processes can reinforce each other within a tumor.

Early trial data for several bispecific antibody candidates in advanced NSCLC has generated notable interest, though — as with any early-phase research — larger confirmatory trials are typically needed before a new drug design becomes part of standard treatment.